# ![@avacta Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::2279270671.png) @avacta Avacta

Avacta posts on X about fda, release, announces, to the the most. They currently have [-----] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::2279270671/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2279270671/c:line/m:interactions.svg)

- [--] Week [------] +241%
- [--] Month [-------] +23%
- [--] Months [-------] +249%
- [--] Year [-------] -32%

### Mentions: [--] [#](/creator/twitter::2279270671/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2279270671/c:line/m:posts_active.svg)


### Followers: [-----] [#](/creator/twitter::2279270671/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2279270671/c:line/m:followers.svg)

- [--] Month [-----] +0.11%
- [--] Months [-----] +1%
- [--] Year [-----] +0.72%

### CreatorRank: undefined [#](/creator/twitter::2279270671/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2279270671/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  [travel destinations](/list/travel-destinations)  [financial services](/list/financial-services)  [stocks](/list/stocks)  [countries](/list/countries) 

**Social topic influence**
[fda](/topic/fda), [release](/topic/release), [announces](/topic/announces), [to the](/topic/to-the), [key](/topic/key), [1b](/topic/1b), [barcelona](/topic/barcelona), [san](/topic/san), [morgan](/topic/morgan), [community](/topic/community)

**Top assets mentioned**
[DOSE (DOSE)](/topic/dose)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Exciting new data from the lab of our collaborator Prof Udai Banerji characterises differences between CAFs and cancer cells and identifies potential new stromal cell targets"  
[X Link](https://x.com/avacta/status/1694292414133911731)  2023-08-23T10:16Z [----] followers, 15.6K engagements


"Interim Results for the Period Ending [--] June [----]. #AVCT"  
[X Link](https://x.com/anyuser/status/1707274673937932783)  2023-09-28T06:02Z [--] followers, 34.3K engagements


"We will be in Boston next week to present positive new data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. See you all there #AVCT #cancerresearch #innovation #oncology"  
[X Link](https://x.com/avacta/status/1709811468684701958)  2023-10-05T06:03Z [----] followers, 33.5K engagements


"Our first poster at the #AACR NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics is now live at It will be presented today 12:30-16:00 US EST. Our second poster will be available when it is presented on Saturday"  
[X Link](https://x.com/avacta/status/1712381915943096578)  2023-10-12T08:17Z [----] followers, 19K engagements


"We will publish a video explainer presentation by Avacta CEO Alastair Smith next week where he will explore the data in both posters being presented at the conference in more detail. #AVCT"  
[X Link](https://x.com/avacta/status/1712381917566255295)  2023-10-12T08:17Z [----] followers, 13.8K engagements


"Avacta CEO Alastair Smith talks through the data in Avacta's AVA32 and AVA3996 posters presented at the AACR-NCI-EORTC International Conference on Molecular Targets. #AVCT"  
[X Link](https://x.com/avacta/status/1713837566510719013)  2023-10-16T08:41Z [----] followers, 35.1K engagements


"Dr. Fiona McLaughlin Avatca's Chief Scientific Officer for Therapeutics has written this summary of the poster presentations given at the recent International Conference on Molecular Targets and Cancer Therapeutics. #AVCT"  
[X Link](https://x.com/avacta/status/1715312871695909170)  2023-10-20T10:23Z [----] followers, 29.7K engagements


"In todays Autumn Statement [--] million seed funding was pledged in the fight against antimicrobial resistance (AMR) to help launch the Fleming Centre in [----]. We look forward to engaging with the centre to promote the critical role of diagnostics in tackling the AMR pandemic"  
[X Link](https://x.com/avacta/status/1727362448938745869)  2023-11-22T16:24Z [----] followers, 10.9K engagements


"Avacta is pleased to provide detailed pre-clinical clinical and pharmacokinetic data from the Phase 1a dose escalation study of its lead preCISION programme AVA6000 a tumour activated form of doxorubicin. #AVCT"  
[X Link](https://x.com/avacta/status/1734831505837314407)  2023-12-13T07:03Z [----] followers, 60K engagements


"The data deck can be downloaded here. Join us at 11:00 where Avactas CEO Alastair Smith CSO Fiona McLaughlin and Consultant Christina Coughlin will present a detailed review of the AVA6000 preclinical and clinical data followed by investor Q&A on the IMC platform. #AVCT"  
[X Link](https://x.com/avacta/status/1734832113399075196)  2023-12-13T07:06Z [----] followers, [----] engagements


"Result of Placing. #AVCT"  
[X Link](https://x.com/avacta/status/1763097451148255548)  2024-02-29T07:02Z [----] followers, 14.6K engagements


"Avacta's Chief Executive Officer Dr. Alastair Smith will be hosting a webinar on Wednesday [--] April [----] at 5:30pm (BST). More info on how to register can be found here: #AVCT https://avacta.com/investor-webinar/ https://avacta.com/investor-webinar/"  
[X Link](https://x.com/avacta/status/1773382347062186128)  2024-03-28T16:11Z [----] followers, 18.5K engagements


"An updated presentation deck 'Targeting the Tumor Microenvironment' has been added to the Investor Resources section of our website access it directly here. A recording of the presentation by Avacta CEO Chris Coughlin will follow. #AVCT https://avacta.com/wp-content/uploads/2024/06/Targeting-the-tumor-microenvironment-June-2024.pdf https://avacta.com/wp-content/uploads/2024/06/Targeting-the-tumor-microenvironment-June-2024.pdf"  
[X Link](https://x.com/avacta/status/1797620413817913769)  2024-06-03T13:24Z [----] followers, 15.1K engagements


"Good to be featured by @joannemidas in MIDAS share tips 'companies working on future blockbuster treatments'. #AVCT https://www.dailymail.co.uk/money/investing/article-13615305/Investors-Ozempic-huge-profits-stock-picking-expert-unearths-companies-working-blockbuster-treatments-future-make-packet.html https://www.dailymail.co.uk/money/investing/article-13615305/Investors-Ozempic-huge-profits-stock-picking-expert-unearths-companies-working-blockbuster-treatments-future-make-packet.html"  
[X Link](https://x.com/avacta/status/1810980927457071394)  2024-07-10T10:14Z [----] followers, 26K engagements


"Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress. #AVCT https://www.globenewswire.com/news-release/2024/09/08/2942471/0/en/Avacta-to-present-updated-clinical-data-on-AVA6000-at-the-European-Society-for-Medical-Oncology-ESMO-Congress.html https://www.globenewswire.com/news-release/2024/09/08/2942471/0/en/Avacta-to-present-updated-clinical-data-on-AVA6000-at-the-European-Society-for-Medical-Oncology-ESMO-Congress.html"  
[X Link](https://x.com/avacta/status/1832905540181123229)  2024-09-08T22:15Z [----] followers, 27.1K engagements


"Avacta is today presenting updated data from the ongoing Phase 1a trial of AVA6000 in patients with FAP-positive solid tumors at the [----] European Society for Medical Oncology (ESMO) Congress in Barcelona Spain. #AVCT https://avacta.com/avacta-reports-updated-phase-1-clinical-data-of-ava6000-at-the-european-society-for-medical-oncology-esmo-congress-demonstrating-multiple-ongoing-durable-responses-in-solid-tumors/"  
[X Link](https://x.com/avacta/status/1834851147665789197)  2024-09-14T07:06Z [----] followers, 44.5K engagements


"We're delighted that Avacta has been shortlisted as a finalist for the [----] @Citeline Scrip Awards in the 'Best Oncology R&D Advance' category. Find more info about the awards at #AVCT https://www.citeline.com/en/awards/scripawards https://www.citeline.com/en/awards/scripawards"  
[X Link](https://x.com/avacta/status/1838233947760644528)  2024-09-23T15:08Z [----] followers, 29.4K engagements


"Avacta CEO @coughlin582 joined the Peel Hunt healthcare team in this podcast to discuss the preCISION platform and ongoing AVA6000 clinical trial. #AVCT https://peelhunthealthcarelifesciences.gallery.video/240924 https://peelhunthealthcarelifesciences.gallery.video/240924"  
[X Link](https://x.com/avacta/status/1838490623080362312)  2024-09-24T08:08Z [----] followers, 25.2K engagements


"In this video presentation Avacta CEO @coughlin582 describes the data presented on our poster at the recent European Society for Medical Oncology (ESMO) conference in Barcelona. #AVCT https://avacta.wistia.com/medias/ye29ii109e https://avacta.wistia.com/medias/ye29ii109e"  
[X Link](https://x.com/avacta/status/1838567883330253118)  2024-09-24T13:15Z [----] followers, 20.4K engagements


"Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology. #AVCT https://avacta.com/avacta-and-tempus-enter-strategic-collaboration-to-advance-ai-driven-drug-development-in-oncology/ https://avacta.com/avacta-and-tempus-enter-strategic-collaboration-to-advance-ai-driven-drug-development-in-oncology/"  
[X Link](https://x.com/avacta/status/1848243516322787608)  2024-10-21T06:02Z [----] followers, 34.3K engagements


"Great to see so much interest in the poster presentations of our two novel preCISION programs at #ENASymp24 #AVCT"  
[X Link](https://x.com/avacta/status/1849418466412863543)  2024-10-24T11:51Z [----] followers, 10.6K engagements


"Watch the video of all presentations from our recent live R&D Spotlight: 'Next Generation of preCISION Medicines'. #AVCT https://avacta.wistia.com/medias/mnziy2sung https://avacta.wistia.com/medias/mnziy2sung"  
[X Link](https://x.com/avacta/status/1854892566614786444)  2024-11-08T14:23Z [----] followers, 14.1K engagements


"Our CEO Christina Coughlin met today at the @ctosociety annual meeting with the Sarcoma Patient Advocacy Global Network (SPAGN) @sarcomapatients to discuss our next chapter for AVA6000 in expansion cohorts. #AVCT"  
[X Link](https://x.com/avacta/status/1857197239069970641)  2024-11-14T23:01Z [----] followers, 18.6K engagements


"Listen to the latest @PeelHunt Healthcare & Life Sciences podcast with Avacta CEO @coughlin582 discussing the recent exciting updates to our pipeline. #AVCT https://peelhunthealthcarelifesciences.gallery.video/241127 https://peelhunthealthcarelifesciences.gallery.video/241127"  
[X Link](https://x.com/avacta/status/1861717402041401836)  2024-11-27T10:23Z [----] followers, [----] engagements


"Dose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open for Enrolment. #AVCT https://avacta.com/dose-escalation-and-recommended-dose-for-expansion-rde-arms-of-the-ava6000-phase-1a-trial-complete-and-phase-1b-disease-specific-expansion-cohorts-open-for-enrolment/ https://avacta.com/dose-escalation-and-recommended-dose-for-expansion-rde-arms-of-the-ava6000-phase-1a-trial-complete-and-phase-1b-disease-specific-expansion-cohorts-open-for-enrolment/"  
[X Link](https://x.com/avacta/status/1867103115805331489)  2024-12-12T07:04Z [----] followers, 18K engagements


"Avacta Announces Positive New Data from the AVA6000 Phase [--] trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers. #AVCT https://avacta.com/avacta-announces-positive-new-data-from-the-ava6000-phase-1-trial-demonstrating-clinically-meaningful-tumor-shrinkage-in-patients-with-salivary-gland-cancers/ https://avacta.com/avacta-announces-positive-new-data-from-the-ava6000-phase-1-trial-demonstrating-clinically-meaningful-tumor-shrinkage-in-patients-with-salivary-gland-cancers/"  
[X Link](https://x.com/avacta/status/1879786283142377512)  2025-01-16T07:02Z [----] followers, 38.6K engagements


"Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update. #AVCT https://avacta.com/avacta-announces-agreement-to-sell-launch-diagnostics-and-a-corporate-update/ https://avacta.com/avacta-announces-agreement-to-sell-launch-diagnostics-and-a-corporate-update/"  
[X Link](https://x.com/avacta/status/1897918289747091834)  2025-03-07T07:52Z [----] followers, [----] engagements


"Avacta Therapeutics to Present at the [----] Leerink Global Healthcare Conference. #AVCT https://avacta.com/avacta-therapeutics-to-present-at-the-2025-leerink-global-healthcare-conference/ https://avacta.com/avacta-therapeutics-to-present-at-the-2025-leerink-global-healthcare-conference/"  
[X Link](https://x.com/avacta/status/1898992551564058829)  2025-03-10T07:01Z [----] followers, 18.7K engagements


"Avacta today announces that Dr. Trevor Nicholls one of the Groups non-executive directors is retiring from the Board with effect from April [--] [----]. #AVCT https://avacta.com/board-change/ https://avacta.com/board-change/"  
[X Link](https://x.com/avacta/status/1917097273537728950)  2025-04-29T06:03Z [----] followers, [----] engagements


"Dr Christina Coughlin Chief Executive Officer and Michelle Morrow Chief Scientific Officer will be presenting at a webinar on [--] May [----] at [----] pm (BST). #AVCT https://www.turnerpope.com/register/ https://www.turnerpope.com/register/"  
[X Link](https://x.com/avacta/status/1921884100358533574)  2025-05-12T11:04Z [----] followers, 13.1K engagements


"Avacta Provides Q2 [----] Business Update Outlining Progress Against Strategic Objectives. #AVCT https://avacta.com/avacta-provides-q2-2025-business-update-outlining-progress-against-strategic-objectives/ https://avacta.com/avacta-provides-q2-2025-business-update-outlining-progress-against-strategic-objectives/"  
[X Link](https://x.com/avacta/status/1940291340379840557)  2025-07-02T06:07Z [----] followers, [----] engagements


"AffyXell joint venture milestone and increased equity stake. #AVCT https://hubs.ly/Q017-y2F0 https://hubs.ly/Q017-y2F0"  
[X Link](https://x.com/avacta/status/1514121802959708162)  2022-04-13T06:02Z [----] followers, [---] engagements


"Successful Completion of Fifth Dose Escalation in AVA6000 Phase [--] Clinical Study. #AVCT https://avacta.com/successful-completion-of-fifth-dose-escalation-in-ava6000-phase-1-clinical-study/ https://avacta.com/successful-completion-of-fifth-dose-escalation-in-ava6000-phase-1-clinical-study/"  
[X Link](https://x.com/avacta/status/1671398312526618627)  2023-06-21T06:03Z [----] followers, 85.7K engagements


"Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update. #AVCT https://avacta.com/successful-completion-of-als-6000-101-sixth-dose-escalation-and-clinical-update/ https://avacta.com/successful-completion-of-als-6000-101-sixth-dose-escalation-and-clinical-update/"  
[X Link](https://x.com/avacta/status/1704012832113828337)  2023-09-19T06:01Z [----] followers, 97.6K engagements


"Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm [--] of Avactas AVA6000 Phase [--] trial. #AVCT @sofiebio https://avacta.com/successful-completion-of-first-cohort-and-dosing-of-three-patients-of-the-second-cohort-in-arm-2-of-avactas-ava6000-phase-1-trial/ https://avacta.com/successful-completion-of-first-cohort-and-dosing-of-three-patients-of-the-second-cohort-in-arm-2-of-avactas-ava6000-phase-1-trial/"  
[X Link](https://x.com/avacta/status/1793522994100502537)  2024-05-23T06:02Z [----] followers, 53.5K engagements


"In episode [--] of our R&D Spotlight Series we look at team dynamics. In this conversation Avacta's Chief Executive Officer Christina Coughlin talks to Chief Operating Officer Karen Harrison. #AVCT https://avacta.wistia.com/medias/f3rl5b4fiz https://avacta.wistia.com/medias/f3rl5b4fiz"  
[X Link](https://x.com/avacta/status/1822978940467662856)  2024-08-12T12:50Z [----] followers, 42.1K engagements


"In Episode [--] of the R&D Spotlight Series the team discuss in detail the preCISION platform and how weve been updating it since AVA6000 went into the clinic. #AVCT https://avacta.wistia.com/medias/w78dwgqnaq https://avacta.wistia.com/medias/w78dwgqnaq"  
[X Link](https://x.com/avacta/status/1833859501708959762)  2024-09-11T13:25Z [----] followers, 85.9K engagements


"Avacta announces a new partial response observed in a patient with salivary gland cancer in the dose expansion phase of the FAP-Dox (AVA6000) Phase 1b trial. #AVCT https://avacta.com/new-response-in-the-fap-dox-ava6000-phase-1b-trial/ https://avacta.com/new-response-in-the-fap-dox-ava6000-phase-1b-trial/"  
[X Link](https://x.com/avacta/status/1935579181380751470)  2025-06-19T06:03Z [----] followers, 36.7K engagements


"Avacta announces the team will present the published data of the platform innovation the preCISION dual payload peptide drug conjugate delivery system following their return from the [----] AACR-NCI-EORTC International Molecular Targets Congress. #AVCT https://avacta.com/notice-of-investor-presentation/ https://avacta.com/notice-of-investor-presentation/"  
[X Link](https://x.com/avacta/status/1981391293151588799)  2025-10-23T16:04Z [----] followers, 25K engagements


"Avacta presents first preclinical data from dual payload preCISION medicines at the [----] AACR-NCI-EORTC International Conference on Molecular Targets. #AVCT https://avacta.com/avacta-presents-first-preclinical-data-from-dual-payload-precision-medicines-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets/ https://avacta.com/avacta-presents-first-preclinical-data-from-dual-payload-precision-medicines-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets/"  
[X Link](https://x.com/anyuser/status/1982135759625761245)  2025-10-25T17:22Z [----] followers, 20.6K engagements


"In Episode [--] of the R&D Spotlight series the team dive into FAP-Exd (AVA6103) and look under the hood of the sustained release mechnism. #AVCT https://avacta.wistia.com/medias/thz9au7cnj https://avacta.wistia.com/medias/thz9au7cnj"  
[X Link](https://x.com/anyuser/status/2001593953091518813)  2025-12-18T10:02Z [----] followers, 27.4K engagements


"Were excited to join the biotech community in San Francisco with the JP Morgan Healthcare Conference & Bio Showcase [----] happening next week. We look forward to seeing you there. #JPM26 #Biotech #AVCT"  
[X Link](https://x.com/anyuser/status/2008470308303278244)  2026-01-06T09:26Z [----] followers, 28.3K engagements


"Avacta announces the appointment of Strand Hanson Limited as the Companys Nominated Adviser with immediate effect. #AVCT https://avacta.com/appointment-of-nominated-adviser/ https://avacta.com/appointment-of-nominated-adviser/"  
[X Link](https://x.com/anyuser/status/2013508290274001163)  2026-01-20T07:06Z [----] followers, [----] engagements


"Avacta has published a trading update for the year ended December [--] [----]. #AVCT https://avacta.com/year-end-trading-update/ https://avacta.com/year-end-trading-update/"  
[X Link](https://x.com/anyuser/status/2013508747109310937)  2026-01-20T07:07Z [----] followers, [----] engagements


"Avacta is pleased to announce U.S. FDA clearance of the IND application for the Companys second program FAP-Exd (AVA6103) the first preCISION peptide drug conjugate based on the highly potent topoisomerase I inhibitor exatecan. #AVCT https://avacta.com/avacta-announces-u-s-food-and-drug-administration-clearance-of-the-investigational-new-drug-ind-application-for-the-second-precision-medicine-fap-exatecan-ava6103/ https://avacta.com/avacta-announces-u-s-food-and-drug-administration-clearance-of-the-investigational-new-drug-ind-application-for-the-second-precision-medicine-fap-exatecan-ava6103/"  
[X Link](https://x.com/anyuser/status/2013870407279853603)  2026-01-21T07:04Z [----] followers, 28.7K engagements


"Our 2nd preCISION medicine is heading to the clinic With FDA clearance of the IND for AVA6103 were one step closer to a new approach for cancer treatment. Were honored to have Dr. Alexander Spira and team joining us on this journey. Phase [--] begins later this quarter. #AVCT"  
[X Link](https://x.com/anyuser/status/2014315391154082083)  2026-01-22T12:33Z [----] followers, 11.7K engagements


"Avacta's Principal Scientist Manuel Pinto today presented a poster 'Affimerbiotherapeutics: Next generation platform for cancer therapies' at the PEGS Europe [----] conference. Read more and download the poster at: https://avacta.com/affimer-biotherapeutics-the-next-generation-of-cancer-therapies/ https://avacta.com/affimer-biotherapeutics-the-next-generation-of-cancer-therapies/"  
[X Link](https://x.com/avacta/status/1724859917163442575)  2023-11-15T18:40Z [----] followers, 29.3K engagements


"Appointment of Simon Bennett as Chief Business Officer of the Therapeutics Division. #AVCT https://avacta.com/appointment-of-chief-business-officer/ https://avacta.com/appointment-of-chief-business-officer/"  
[X Link](https://x.com/avacta/status/1737005712255955138)  2023-12-19T07:03Z [----] followers, 42.3K engagements


"Shaun Chilton is appointed Non-Executive Chairman of the Avacta Board of Directors. #AVCT https://avacta.com/shaun-chilton-is-appointed-non-executive-chairman-of-the-avacta-board-of-directors/ https://avacta.com/shaun-chilton-is-appointed-non-executive-chairman-of-the-avacta-board-of-directors/"  
[X Link](https://x.com/avacta/status/1803669725496393800)  2024-06-20T06:02Z [----] followers, 30.8K engagements


"The preclinical and translational data being presented on two posters by the Avacta team today at #AACR25 are now available to view on our website at A third poster on safety and efficacy data for AVA6000 will go live at the same time tomorrow. #AVCT https://avacta.com/about/scientific-resources/ https://avacta.com/about/scientific-resources/"  
[X Link](https://x.com/avacta/status/1916927014386471040)  2025-04-28T18:46Z [----] followers, 11.4K engagements


"Avacta has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. #AVCT https://avacta.com/avacta-announces-two-key-clinical-updates-to-its-faridoxorubicin-program/ https://avacta.com/avacta-announces-two-key-clinical-updates-to-its-faridoxorubicin-program/"  
[X Link](https://x.com/anyuser/status/2018592977283862550)  2026-02-03T07:50Z [----] followers, 35.6K engagements


"We are delighted to announce the appointment of chemistryexpertFrancis Wilson as our new Chief Scientific Officer. The appointmentprovides further impetus toAvacta asweadvanceourinnovative tumor-targeted therapies to patients in need. #AVCT https://avacta.com/avacta-appoints-francis-wilson-as-chief-scientific-officer/ https://avacta.com/avacta-appoints-francis-wilson-as-chief-scientific-officer/"  
[X Link](https://x.com/avacta/status/2020755181554512145)  2026-02-09T07:02Z [----] followers, 24.8K engagements


"We're proud to lauch our new podcast series - Avacta Academy: The Nuts and Bolts of Drug Development Explained. Want to learn more about how the business of drug development actually works Join us for a fascinating look at the key steps on the pathway from idea to a drug. #AVCT"  
[X Link](https://x.com/anyuser/status/2022259497364762628)  2026-02-13T10:40Z [----] followers, [----] engagements


"In episode one Avactas management team breaks down all the work that goes into an IND and why its an important milestone on the way to reaching patients with a new drug. #AVCT https://avacta.wistia.com/medias/w8k1mnx8oj https://avacta.wistia.com/medias/w8k1mnx8oj"  
[X Link](https://x.com/anyuser/status/2022259498962874825)  2026-02-13T10:40Z [----] followers, [----] engagements


"We are delighted to announce the appointment of chemistryexpertFrancis Wilson as our new Chief Scientific Officer. The appointmentprovides further impetus toAvacta asweadvanceourinnovative tumor-targeted therapies to patients in need. #AVCT https://avacta.com/avacta-appoints-francis-wilson-as-chief-scientific-officer/ https://avacta.com/avacta-appoints-francis-wilson-as-chief-scientific-officer/"  
[X Link](https://x.com/avacta/status/2020755181554512145)  2026-02-09T07:02Z [----] followers, 24.8K engagements


"Avacta has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. #AVCT https://avacta.com/avacta-announces-two-key-clinical-updates-to-its-faridoxorubicin-program/ https://avacta.com/avacta-announces-two-key-clinical-updates-to-its-faridoxorubicin-program/"  
[X Link](https://x.com/anyuser/status/2018592977283862550)  2026-02-03T07:50Z [----] followers, 35.6K engagements


"Our 2nd preCISION medicine is heading to the clinic With FDA clearance of the IND for AVA6103 were one step closer to a new approach for cancer treatment. Were honored to have Dr. Alexander Spira and team joining us on this journey. Phase [--] begins later this quarter. #AVCT"  
[X Link](https://x.com/anyuser/status/2014315391154082083)  2026-01-22T12:33Z [----] followers, 11.7K engagements


"Avacta is pleased to announce U.S. FDA clearance of the IND application for the Companys second program FAP-Exd (AVA6103) the first preCISION peptide drug conjugate based on the highly potent topoisomerase I inhibitor exatecan. #AVCT https://avacta.com/avacta-announces-u-s-food-and-drug-administration-clearance-of-the-investigational-new-drug-ind-application-for-the-second-precision-medicine-fap-exatecan-ava6103/ https://avacta.com/avacta-announces-u-s-food-and-drug-administration-clearance-of-the-investigational-new-drug-ind-application-for-the-second-precision-medicine-fap-exatecan-ava6103/"  
[X Link](https://x.com/anyuser/status/2013870407279853603)  2026-01-21T07:04Z [----] followers, 28.7K engagements


"Avacta has published a trading update for the year ended December [--] [----]. #AVCT https://avacta.com/year-end-trading-update/ https://avacta.com/year-end-trading-update/"  
[X Link](https://x.com/anyuser/status/2013508747109310937)  2026-01-20T07:07Z [----] followers, [----] engagements


"Avacta announces the appointment of Strand Hanson Limited as the Companys Nominated Adviser with immediate effect. #AVCT https://avacta.com/appointment-of-nominated-adviser/ https://avacta.com/appointment-of-nominated-adviser/"  
[X Link](https://x.com/anyuser/status/2013508290274001163)  2026-01-20T07:06Z [----] followers, [----] engagements


"Were excited to join the biotech community in San Francisco with the JP Morgan Healthcare Conference & Bio Showcase [----] happening next week. We look forward to seeing you there. #JPM26 #Biotech #AVCT"  
[X Link](https://x.com/anyuser/status/2008470308303278244)  2026-01-06T09:26Z [----] followers, 28.3K engagements


"In Episode [--] of the R&D Spotlight series the team dive into FAP-Exd (AVA6103) and look under the hood of the sustained release mechnism. #AVCT https://avacta.wistia.com/medias/thz9au7cnj https://avacta.wistia.com/medias/thz9au7cnj"  
[X Link](https://x.com/anyuser/status/2001593953091518813)  2025-12-18T10:02Z [----] followers, 27.4K engagements


"Avacta today announced new pharmacology data with its second asset FAP-Exd (AVA6103) which is anticipated to begin Phase [--] testing in Q1 [----]. #AVCT https://avacta.com/avacta-reports-new-pharmacology-data-for-fap-exd-ava6103/ https://avacta.com/avacta-reports-new-pharmacology-data-for-fap-exd-ava6103/"  
[X Link](https://x.com/anyuser/status/2001549189574996458)  2025-12-18T07:04Z [----] followers, [----] engagements


"Our CEO @coughlin582 and COO Karen Harrison were thrilled to visit our manufacturing partner Curia this week to witness the some of the last steps in the manufacturing process for our next program FAP-Exd (AVA6103). Looking forward to the next stage of development #AVCT"  
[X Link](https://x.com/anyuser/status/2001247875196707001)  2025-12-17T11:07Z [----] followers, 21.6K engagements


"Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers. #AVCT https://avacta.com/faridoxorubicin-ava6000-phase-1b-cohort-demonstrates-clinically-meaningful-tumor-shrinkage-in-patients-with-salivary-gland-cancers/ https://avacta.com/faridoxorubicin-ava6000-phase-1b-cohort-demonstrates-clinically-meaningful-tumor-shrinkage-in-patients-with-salivary-gland-cancers/"  
[X Link](https://x.com/anyuser/status/2001187222528078266)  2025-12-17T07:06Z [----] followers, 12.9K engagements


"Join AVACTA GROUP PLC's Phase 1b Faridoxorubicin (AVA6000) Salivary Gland Cancer Data Release TOMORROW at 10:00am - Click below to register. #AVCT @avacta https://www.investormeetcompany.com/avacta-group-plc/register-investorutm_source=twitter&utm_medium=social&utm_campaign=meeting_reminder_24_hour https://www.investormeetcompany.com/avacta-group-plc/register-investorutm_source=twitter&utm_medium=social&utm_campaign=meeting_reminder_24_hour"  
[X Link](https://x.com/anyuser/status/2000853712961404985)  2025-12-16T09:01Z [----] followers, [----] engagements


"Our Principal Scientist Victoria Juskaite presented at Tumour Model Summit London [----] last week. Her talk explored how spheroid co-cultures and PDX models are helping Avacta optimise the translation of our preCISION PDC's into targeted cancer therapies. #AVCT"  
[X Link](https://x.com/anyuser/status/1998758529918992537)  2025-12-10T14:15Z [----] followers, 11.1K engagements


"Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort. #AVCT https://avacta.com/avacta-announces-the-preliminary-clinical-data-in-the-faridoxorubicin-phase-1b-trial-in-the-salivary-gland-cancer-cohort/ https://avacta.com/avacta-announces-the-preliminary-clinical-data-in-the-faridoxorubicin-phase-1b-trial-in-the-salivary-gland-cancer-cohort/"  
[X Link](https://x.com/anyuser/status/1997941146459472130)  2025-12-08T08:07Z [----] followers, 11.4K engagements


"Delighted to share a great conversation about #AVCT with Tom Weir on the Biohub podcast Ep [--]. An exciting time for Avacta is on the horizon #HopeWithoutCompromise https://www.linkedin.com/posts/christina-coughlin-809abb13_we-were-delighted-to-welcome-christina-activity-7402741906536894464-ItPXutm_medium=ios_app&rcm=ACoAAALVMckBlcZxNKejYiwMWZxuel1GuPB6spY&utm_source=social_share_send&utm_campaign=x"  
[X Link](https://x.com/anyuser/status/1997036027614318688)  2025-12-05T20:11Z [----] followers, 15.2K engagements


"#LondonLifeSciences Week. Avacta Tx thrilled to be selected as the Company to Watch using AI as an accelerator in drug development. So proud of our team and everything we have accomplished. #AVCT #HopeWithoutCompromise https://www.linkedin.com/posts/christina-coughlin-809abb13_llsw2025-activity-7396913557822521344-hTeputm_medium=ios_app&rcm=ACoAAALVMckBlcZxNKejYiwMWZxuel1GuPB6spY&utm_source=social_share_send&utm_campaign=x"  
[X Link](https://x.com/anyuser/status/1991150752841048164)  2025-11-19T14:25Z [----] followers, 13.5K engagements


"Completion of Placing and TVR. #AVCT https://avacta.com/completion-of-placing-and-tvr/ https://avacta.com/completion-of-placing-and-tvr/"  
[X Link](https://x.com/anyuser/status/1985262664902181125)  2025-11-03T08:27Z [----] followers, [----] engagements


"Avacta presents first preclinical data from dual payload preCISION medicines at the [----] AACR-NCI-EORTC International Conference on Molecular Targets. #AVCT https://avacta.com/avacta-presents-first-preclinical-data-from-dual-payload-precision-medicines-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets/ https://avacta.com/avacta-presents-first-preclinical-data-from-dual-payload-precision-medicines-at-the-2025-aacr-nci-eortc-international-conference-on-molecular-targets/"  
[X Link](https://x.com/anyuser/status/1982135759625761245)  2025-10-25T17:22Z [----] followers, 20.6K engagements


"Download the poster being presented at the AACR-NCI-EORTC conference here: #AVCT https://avacta.com/about/scientific-resources/ https://avacta.com/about/scientific-resources/"  
[X Link](https://x.com/anyuser/status/1982135761286660541)  2025-10-25T17:22Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing